Cytokinetics Inc (CYTK)
55.99
-0.22
(-0.38%)
USD |
NASDAQ |
Nov 13, 16:00
55.99
0.00 (0.00%)
After-Hours: 20:00
Cytokinetics Revenue (TTM): 3.219M for Sept. 30, 2024
Revenue (TTM) Chart
Historical Revenue (TTM) Data
| Date | Value |
|---|---|
| September 30, 2024 | 3.219M |
| June 30, 2024 | 3.134M |
| March 31, 2024 | 3.752M |
| December 31, 2023 | 7.53M |
| September 30, 2023 | 7.815M |
| June 30, 2023 | 9.952M |
| March 31, 2023 | 98.05M |
| December 31, 2022 | 94.59M |
| September 30, 2022 | 148.23M |
| June 30, 2022 | 151.15M |
| March 31, 2022 | 65.03M |
| December 31, 2021 | 70.43M |
| September 30, 2021 | 21.55M |
| June 30, 2021 | 57.80M |
| March 31, 2021 | 58.55M |
| December 31, 2020 | 55.83M |
| September 30, 2020 | 54.32M |
| June 30, 2020 | 18.68M |
| March 31, 2020 | 22.23M |
| December 31, 2019 | 26.87M |
| September 30, 2019 | 31.03M |
| June 30, 2019 | 35.62M |
| March 31, 2019 | 34.70M |
| December 31, 2018 | 31.50M |
| September 30, 2018 | 22.11M |
| Date | Value |
|---|---|
| June 30, 2018 | 17.64M |
| March 31, 2018 | 14.48M |
| December 31, 2017 | 13.37M |
| September 30, 2017 | 46.52M |
| June 30, 2017 | 99.39M |
| March 31, 2017 | 102.14M |
| December 31, 2016 | 106.41M |
| September 30, 2016 | 83.03M |
| June 30, 2016 | 31.92M |
| March 31, 2016 | 32.66M |
| December 31, 2015 | 28.66M |
| September 30, 2015 | 40.66M |
| June 30, 2015 | 42.13M |
| March 31, 2015 | 43.38M |
| December 31, 2014 | 46.94M |
| September 30, 2014 | 49.53M |
| June 30, 2014 | 44.58M |
| March 31, 2014 | 37.81M |
| December 31, 2013 | 30.65M |
| September 30, 2013 | 8.483M |
| June 30, 2013 | 5.728M |
| March 31, 2013 | 6.56M |
| December 31, 2012 | 7.559M |
| September 30, 2012 | 6.132M |
| June 30, 2012 | 5.845M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
3.134M
Minimum
Jun 2024
151.15M
Maximum
Jun 2022
48.94M
Average
40.59M
Median
Revenue (TTM) Benchmarks
| Alnylam Pharmaceuticals Inc | 2.095B |
| Biomarin Pharmaceutical Inc | 2.753B |
| Catalyst Pharmaceuticals Inc | 460.48M |
| Sarepta Therapeutics Inc | 1.640B |
| Ocugen Inc | -- |